Detection of Beclomethasone in urine and dried blood spots in healthy subjects, after inhalation of therapeutic doses, for doping control analysis

Code: 21C14AR

This project i a three-armed randomised controlled trial investigating the effect of WADA approved anti asthmatic medication on sprint performance during submaximal cycling. In addition to performance testing we will analyse urine and dried blood spot samples produce reference values for approved use of the respective medication. We will administer the newly WADA approved beta2 agonist vilanterol in combination with flutikasonfuroat, beclomethasone or placebo to 45 non asthmatic well-trained cyclists or triathletes. Performance test and analysis of urine will be performed after a single dose and one week’s use.

The study will address knowledge gaps regarding the effect approved doses of beta2 agonists identified by meta-analysis published in 2020 and knowledge gaps identified by a systematic review of regarding glucocorticoid administration in athletes. Our research will contribute to establishing thresholds to distinguish approved from prohibited use and develop new methods for analysis. *Research hypothesis and objectives The overall aims of the present study are to investigate the effect the of WADA approved anti-asthmatic medication vilanterol and beclomethasone on physical performance in health athletes, and to investigate the concentration levels and inter-subject variability in both urine and dried blood spots for establishment of levels consistent with therapeutic use.

In detail vilanterol and beclomethasone will be investigated to asses:

1. the effect on anaerobic performance during and after prolonged sub-maximal endurance exercise in well trained non-asthmatic athletes

2. the urine concentrations after prolonged endurance activity in athletes after acute and short-term daily inhalation of therapeutic doses

3. the utility of dried blood spots for detection of approved use after prolonged endurance activity